Multiple and secondary hormone secretion in patients with metastatic pancreatic neuroendocrine tumours

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 2, 2016, Pages 445-452

  Crona, Joakim ^a   Norlén, Olov ^b   Antonodimitrakis, Pantelis ^a   Welin, Staffan ^a   Stålberg, Peter ^b   Eriksson, Barbro ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; PANCREAS HORMONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; METASTATIC PANCREATIC NEUROENDOCRINE TUMOR; MORBIDITY; MORTALITY; NEUROENDOCRINE TUMOR; PANCREAS TUMOR; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SWEDEN; COHORT ANALYSIS; GASTROINTESTINAL TUMOR; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; SECONDARY; SECRETION (PROCESS); SMALL INTESTINE; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; INSULIN; INTESTINE, SMALL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PANCREATIC HORMONES; PANCREATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84959450572     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2436     Document Type: Article

References (34)

1. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol. 2008;26: 3063-3072.
2. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res. 2008;14:7798-7803.
3. Faggiano A, Ferolla P, Grimaldi F, et al. Natural history of gastroentero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. J Endocrinol Invest. 2012;35:817-823.
4. Grande E, Capdevila J, Barriuso J, Anton-Aparicio L, Castellano D. Gastroenteropancreatic neuroendocrine tumor cancer stem cells: do they exist? Cancer Metastas Rev. 2012;31:47-53.
5. Kloppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21:15-31.
6. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61-72.
7. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19:753-781.
8. Ardill JE, Erikkson B. The importance of the measurement of circulating markers in patients with neuroendocrine tumours of the pancreas and gut. Endocr Relat Cancer. 2003;10:459-462.
9. Kloppel G, Willemer S, Stamm B, Hacki WH, Heitz PU. Pancreatic lesions and hormonal profile of pancreatic tumors in multiple endocrine neoplasia type I. An immunocytochemical study of nine patients. Cancer. 1986;57:1824-1832.
10. Eriksson B, Arnberg H, Lindgren PG, et al. Neuroendocrine pancreatic tumours: clinical presentation, biochemical and histopathological findings in 84 patients. J Intern Med. 1990;228:103-113.
11. Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with the Zollinger-Ellison syndrome. NEngl J Med. 1986;315:1-5.
12. Wynick D, Williams SJ, Bloom SR. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med. 1988;319:605-607.
13. Chiang HC, O'Dorisio TM, Huang SC, Maton PN, Gardner JD, Jensen RT. Multiple hormone elevations in Zollinger-Ellison syndrome. Prospective study of clinical significance and of the development of a second symptomatic pancreatic endocrine tumor syndrome. Gastroenterology. 1990;99:1565-1575.
14. de Mestier L, Hentic O, Cros J, et al. Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a caseseries study. Ann Intern Med. 2015;162:682-689.
15. Jensen RT, Cadiot G, BrandiML,et al. ENETSconsensus guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95:98-119.
16. Falconi M, Bartsch DK, Eriksson B, et al. ENETS consensus guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology. 2012;95:120-134.
17. Norlen O, Stalberg P, Oberg K, et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg. 2012;36:1419-1431.
18. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. Geneva: World Health Organization; 2010.
19. Nieman LK, Biller BM, Findling JW, et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2008;93:1526-1540.
20. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009;94:709-728.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
22. Osswald A, Plomer E, Dimopoulou C, et al. Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease. Eur J Endocrinol. 2014;171:209-215.
23. Madeira I, Terris B, VossM,et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut. 1998;43: 422-427.
24. Oberg K, Modlin IM, De Herder W, et al. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015;16:e435-e446.
25. Chera S, Baronnier D, Ghila L, et al. Diabetes recovery by agedependent conversion of pancreatic α-Cells into insulin producers. Nature. 2014;514(7523):503-507.
26. Bramswig NC, Everett LJ, Schug J, et al. Epigenomic plasticity enables human pancreatic α to cell reprogramming. J Clin Invest. 2013;123:1275-1284.
27. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013;62:2595-2604.
28. Habener JF, Kemp DM, Thomas MK. Minireview: transcriptional regulation in pancreatic development. Endocrinology. 2005;146: 1025-1034.
29. Larsson LI, Grimelius L, Hakanson R, et al. Mixed endocrine pancreatic tumors producing several peptide hormones. Am J Pathol. 1975;79:271-284.
30. Rindi G, Grant SG, Yiangou Y, et al. Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice. Heterogeneity of hormone expression. Am J Pathol. 1990;136:1349-1363.
31. Kim JY, Kim MS, Kim KS, et al. Clinicopathologic and prognostic significance of multiple hormone expression in pancreatic neuroendocrine tumors. Am J Surg Pathol. 2015;39(5):592-601.
32. Hessman O, Skogseid B, Westin G, Akerstrom G. Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors. J Clin Endocrinol Metab. 2001;86:1355-1361.
33. Francis JM, Kiezun A, Ramos AH, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013;45:1483-1486.
34. Crona J, Gustavsson T, Norlen O, et al. Somatic mutations and genetic heterogeneity at the CDKN1B locus in small intestinal neuroendocrine tumors. Ann Surg Oncol. 2015;22(Suppl 3):1428-1435.